A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Clinical trial NCT02156804 · COMPLETED
Trial details
- NCT number
- NCT02156804
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-07
- Primary completion
- 2019-01-18
- Enrollment
- 1009
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.